{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.166","pValueComment":"Two-sided p-value.","statisticalMethod":"Exact Poisson calculation"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"2.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"24"}],"units":"Participants"}],"description":"Incident events are defined as having HGAIN (e.g., AIN 2 or 3, or perianal intraepithelial neoplasia grade 2 or 3) with HPV 18 positive DNA in participants without HPV 18 related HGAIN at baseline.","groups":[{"description":"HPV 18 negative based on serum at visit 0 and DNA from visit 0 and 3 from any anatomical site.","id":"OG000","title":"Naive to HPV 18"},{"description":"HPV 18 positive based on serum at visit 0.","id":"OG001","title":"Prior Exposure to HPV 18"}],"paramType":"NUMBER","populationDescription":"Eligible participants without prevalent HPV 18 related HGAIN at baseline who received at least one vaccination and returned after month 7 with evaluable anal/perianal histology and PCR samples.","reportingStatus":"POSTED","timeFrame":"Post month 7 through month 24","title":"Incidence of HGAIN Associated With HPV 18","type":"PRIMARY","unitOfMeasure":"per 100 person years"}